GlassScriptPhysician profile
Hunter Day
NPI 1407583529
$3,742.31
in general payments reported to CMS, 2019-2025
17 companies · $1,753 in 2025
The $1,753 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $201 · 2023: $837 · 2024: $951 · 2025: $1,753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,313 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,312.58 |
| Education | $228.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,133.31 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $494.79 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $462.79 | 2022-2025 | Dupixent |
| Janssen Biotech, INC. | $387.19 | 2025 | Tremfya |
| Lilly USA, LLC | $384.35 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Genzyme Corporation | $231.84 | 2024-2025 | |
| Galderma Laboratories, L.P. | $185.47 | 2025 | Nemluvio |
| Paratek Pharmaceuticals, INC. | $140.32 | 2025 | Nuzyra |
| Pfizer INC. | $76.78 | 2025 | |
| Sanofi-Aventis U.S. LLC | $69.99 | 2022 | |
| Amgen INC. | $58.80 | 2024-2025 | Otezla, Otezla |
| Ucb, INC. | $24.14 | 2025 | Bimzelx |
| Incyte Corporation | $23.65 | 2025 | Opzelura |
| Sun Pharmaceutical Industries INC. | $21.04 | 2025 | |
| Organon LLC | $17.56 | 2025 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $15.17 | 2025 | Zoryve |
| Smith+Nephew, INC. | $15.12 | 2024 | Collagenase Santyl |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hunter Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.